Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection

Hepatology

Volumn 24, Issue 5, 1996, Pages 991-995

  Marinos, George ^a   Naoumov, Nikolai V ^a   Williams, Roger ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HLA ANTIGEN CLASS 2; LAMIVUDINE; NUCLEOSIDE ANALOG; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ADULT; ARTICLE; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HELPER CELL; HEPATITIS B; HUMAN; HUMAN CELL; LIVER BIOPSY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 0029957570     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008903365     Document Type: Article

References (22)

1. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119:312-323.
2. Krogsgaard K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S, Carreno V, et al. The treatment effect of alpha-interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. J Hepatol 1994; 21:646-655.
3. Peters M. Mechanisms of action of interferons. Semin Liver Dis 1989;9: 235-239.
4. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
5. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, Cavalli A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990;145: 3442-3449.
6. Jung MC, Diepolder HM, Spengler U, Wierenga EA, Zachoval R, Hoffmann RM, Eichenlaub D, et al. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995;69: 3358-3368.
7. Marinos G, Torre F, Chokshi S, Hussain M, Clarke BE, Rowlands DJ, Eddleston ALWF, et al. Induction of T helper cell response to HBcAg in chronic hepatitis B; a major factor in activation of the host immune response to the hepatitis B virus. HEPATOLOGY 1995;20:1040-1049.
8. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. HEPATOLOGY 1989;10:761-763.
9. Twu JS, Lee CH, Lin PM, Schloemer RH. Hepatitis B virus suppresses expression of human beta interferon. Proc Natl Acad Sci U S A 1988;85: 252-256.
10. Whitten T, Quets A, Schloemer R. Identification of the hepatitis B virus factor that inhibits expression of the beta interferon gene. J Virol 1991; 65:4699-4704.
11. Onji M, Lever AM, Saito I, Thomas HC. Defective response to interferons in cells transfected with the hepatitis B virus genome. HEPATOLOGY 1989; 9:92-96.
12. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499.
13. Schalm SW, De Man RA, Heijtingk RA, Niesters HGM. New nucleoside analogues for chronic hepatitis B. J Hepatol 1995;22(suppl 1):52-56.
14. Severini A, Liu XY, Wilson JS, Tyrrell DLJ. Mechanism of inhibition of duck hepatitis B virus polymerase by (-) beta L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1995;39:1430-1435.
15. Tyrrell DLJ, Mitchell MC, Deman RA, Schalm SW, Main J, Thomas HC, Fevery J, et al. Phase-II trial of lamivudine for chronic hepatitis-B [Abstract] HEPATOLOGY 1993;18:A112.
16. Perrillo RP, Minims L, Schechtman K, Robbins D, Campbell C. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. HEPATOLOGY 1993;18:1306-1312.
17. Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR. The serology of chronic hepatitis B infection revisited. J Clin Invest 1993;91: 2586-2595.
18. Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T cell-independent and T cell-dependent antigen. Science 1986;234:1398-1401.
19. Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, Hwang LH, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest 1992;89:87-96.
20. Maruyama T, Iino S, Koike K, Yasuda K, Milich DR. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 1993; 105:1141-1151.
21. Honkoop P, de Man RA, Heytink RA, Schalm SW. Hepatitis B reactivation after lamivudine [letter]. Lancet 1995;346:1156-1157.
22. Janssen HLA, Schalm SW, Berk L, de Man RA, Heijtink RA. Repeated courses of α-interferon for treatment of chronic hepatitis B. J Hepatol 1993;17(suppl 3):S47-S51.